Status:
COMPLETED
A Qualitative Exploration of the Impact of Positive BRCA1/2 Mutation Status on the Lives of Young Women
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
BRCA1 Gene
BRCA2 Gene
Eligibility:
FEMALE
18-100 years
Brief Summary
Background: * Mutations detected in the BRCA1 or BRCA2 genes have been show to produce very high risks of breast and ovarian cancer (as high as 90% and 60%, respectively), as well as accompanying ris...
Detailed Description
Background: * BRCA1/2 mutations are present in approximately 1 in 800 individuals in the US, with higher frequency among some populations (e.g., Ashkenazi Jews) * Mutations confer a lifetime breast c...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Participants must be biologically female
- Participants must have reached their 18th birthday but not have passed their 35th birthday
- Participants must be able to speak and understand English with a level of fluency sufficient for completion of the recorded telephone interview
- Participants must have completed genetic testing for BRCA1/2 and received a positive test result (i.e., a deleterious or disease-related mutation was identified).
- Participants must have experienced or be contemplating/planning couple relationship(s), formation of a family, and/or utilization of risk management/reduction strategies at some point.
- EXCLUSION CRITERIA:
- Potential participants will be excluded from the study if they do not agree to have their interview or focus group contributions audio recorded.
Exclusion
Key Trial Info
Start Date :
June 21 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 3 2015
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT00858078
Start Date
June 21 2011
End Date
April 3 2015
Last Update
November 30 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892